4503.T Astellas Pharma Inc.
JPXHealthcareAs of 2026-08-07 15:30
Why 4503.T matters now
Astellas Pharma Inc. (4503.T) is a Japan stock in Healthcare. The latest InvestLog snapshot shows ¥2,327.00 with +1.68% on the session and ¥4.17T in market capitalization.
Valuation context is available even where detailed statement rows are sparse: InvestLog currently shows P/E 14.30, gross margin 76.1%, and operating margin 18.9%.
Valuation
P/E (TTM)
14.30
PEG
—
P/B
2.28
P/S
1.95
EV/EBITDA
7.51
DCF Value
—
FCF Yield
12.2%
Div Yield
3.4%
Margins & Returns
Gross Margin
76.1%
Operating Margin
18.9%
Net Margin
13.6%
ROE
17.4%
ROA
8.2%
ROIC
12.1%
Listing Info
Market
Japan
Exchange
JPX
Currency
JPY
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
JP
Astellas Pharma Inc., a venerable Japanese pharmaceutical enterprise established in 1923 and headquartered in Tokyo, operates globally in the research, development, manufacturing, and commercialization of a diverse range of medications. Its extensive product lineup addresses critical health needs, including various oncology treatments such as XTANDI for prostate cancer, XOSPATA, an FLT3 inhibitor for specific relapsed or refractory acute myeloid leukemia, and PADCEV for advanced urothelial cancer. For urological conditions, Astellas offers Betanis/Myrbetriq/BETMIGA to manage symptoms of overactive bladder, mirabegron for neurogenic detrusor overactivity in children, and Vesicare for OAB. Other notable pharmaceuticals include Eligard for prostate cancer, Harnal/Omnic for benign prostatic hyperplasia, Evrenzo for anemia associated with chronic kidney disease, and the immunosuppressants Prograf/Advagraf/Graceptor/ASTAGRAF, vital for preventing organ transplant rejection. The company also markets Funguard/MYCAMINE, an antifungal agent. Astellas actively fosters innovation through numerous strategic collaborations and partnerships. These include clinical trial agreements with pharmaceutical giants like Merck & Co., Inc. and CytomX Therapeutics, Inc. Demonstrating a broader approach to health, they collaborate with BANDAI NAMCO Entertainment Inc. on developing a smartphone exercise support application. In the realm of scientific discovery, Astellas maintains a research alliance with Harvard University for joint therapeutic and technological advancements. Further research initiatives involve Actinium Pharmaceuticals, Inc. to advance targeted radiotherapies leveraging their Antibody Warhead Enabling platform, an agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694, and a collaboration with Cytokinetics, Incorporated. A significant strategic alliance and license agreement exist with Minovia Therapeutics Ltd. to research, develop, and commercialize cell therapies for mitochondrial dysfunction.